Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

Neurology

Volumn 66, Issue 6, 2006, Pages 919-921

  Schifitto, G ^a,d   Peterson, D R ^a   Zhong, J ^a   Ni, H ^a   Cruttenden, K ^a   Gaugh, M ^a   Gendelman, H E ^b   Boska, M ^c   Gelbard, H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Clinical Trials Coordination Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; VALPROIC ACID;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; PILOT STUDY; PSYCHOLOGICAL ASPECT;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; VALPROIC ACID;

EID: 33645837210     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000204294.28189.03     Document Type: Article

References (10)

1. Tong N, Sanchez JF, Maggirwar SB, et al. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 2001;13:1913-1922.
2. Dou H, Birusingh K, Faraci J, et al. Neuroprotective activities of sodium valproate in a murine model of HIV-1 encephalitis. J Neurosci 2003;23:9162-9170.
3. Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive motor disorder. Neurology 1996;47:1247-1253.
4. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
5. Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol 1996;77:1993-1999.
6. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366:549-555.
7. 1H magnetic resonance spectroscopic imaging. Neurology 1993;43:509-515.
8. Stankoff B, Tourbah A, Suarez S, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 2001;56:112-115.
9. Chang L, Ernst T, Leonido-Yee M, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999;53:782-789.
10. DiCenzo R, Peterson D, Cruttenden K, Morse G, Gelbard H, Schifitto G. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004;48:4328-4331.